89bioの空売り状況は、投資家が89bioの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

89bio (NASDAQ:ETNB) 株価情報, 空売り情報

89bio

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

89bio Inc

Morgan Stanley analyst Betsy Graseck maintains Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) with a Underweight and lowers the price target from $585 to $450.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Underweight on Lennox Intl, Lowers Price Target to $450

PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.49) by 8.16 percent. This is a 11.76 percent increase over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $69.16 million which beat the analyst consensus estimate of $65.68 million by 5.29 percent. This is a 55.28 percent increase over sales of $44.54 million the same period last year.

Earnings

Earnings Beats

PRCT

PROCEPT BioRobotics Q1 EPS $(0.45) Beats $(0.49) Estimate, Sales $69.16M Beat $65.68M Estimate

We confirm our full-year 2025 earnings guidance range of $11.10 to $11.60 per diluted share, which includes the impact of year-to-date tax benefits of $0.10. As we approach the swimming pool season, we remain focused on strengthening our industry-leading position through disciplined execution, continued innovation of our customer-centric POOL360 digital ecosystem, growing our sales center network and a relentless commitment to helping our customers grow their businesses," said Arvan.

Guidance

POOL

Pool Affirms FY2025 Adj EPS Guidance Of $11.00-$11.50 vs $11.25 Estimate

Breadth of Data Demonstrates Growing Real-World Adoption and Clinical Importance of CareDx Testing Solutions in Heart and Lung Transplant Patient Management
New SHORE Study Findings Demonstrate that HeartCare is Prognostic of Long-Term Outcomes and Informs Treatment Decisions

Biotech

Events

General

CDNA

CareDx Presents 60 Abstracts At 2025 International Society For Heart And Lung Transplantation Meeting

Rosenblatt analyst Blair Abernethy maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Buy and raises the price target from $95 to $101.

PEGA

Rosenblatt Maintains Buy on Pegasystems, Raises Price Target to $101

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is set to report its Q2 2025 earnings on May 1st, Let's see what the charts suggest so far in line with the Adhishthana Principles.
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="557" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24064800/Apple-Chart-View-1.png" alt="Apple Weekly Technical Chart " class="wp-image-11466" style="width:811px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24064800/Apple-Chart-View-1.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24064800/Apple-Chart-View-1-300x139.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24064800/Apple-Chart-View-1-1024x475.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24064800/Apple-Chart-View-1-768x356.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Apple Technical Chart (Weekly)</figcaption></figure>
Currently, Apple is trading within the C5 phase of its Adhishthana market cycle, a stage where a test of the prior C4 phase low at $164.08 is expected. After entering C5 at $224.02, the stock climbed to an interim high of $250.00, then reversed sharply in line with the principles. It recently bottomed at $169.21, coming close to the C4 low.
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1080" height="1080" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062534/Apple-Key-Levels.png" alt="Apple Key Levels " class="wp-image-11454" style="width:320px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062534/Apple-Key-Levels.png 1080w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062534/Apple-Key-Levels-300x300.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062534/Apple-Key-Levels-1024x1024.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062534/Apple-Key-Levels-150x150.png 150w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062534/Apple-Key-Levels-768x768.png 768w" sizes="(max-width: 1080px) 100vw, 1080px" /><figcaption class="wp-element-caption">Apple Key Phase Levels</figcaption></figure>
<div style="height:27px" aria-hidden="true" class="wp-block-spacer"></div>
With these levels in mind, let&#8217;s now assess the structural implications:
The C4 low of $164.08 is expected to serve as a strong support level during the volatile trading sessions leading up to earnings.
The C5 phase has formed eight red bars, suggesting that a final downward move is likely before the structure shifts, with the C4 low continuing to act as a stabilizing support.
Apple's price behavior in the coming sessions will determine the course of the next five-phase Cakra cycle, shaping the stock's medium-term trajectory.
<div style="height:26px" aria-hidden="true" class="wp-block-spacer"></div>
Fundamentals Check 
In the last quarter, Apple reported $124.3 billion in revenue. Operating income stood at $42.83 billion, with total operating expenses of $15.44 billion. The company posted a net income of $36.33 billion, resulting in earnings per share (EPS) of $2.41. From the principles standpoint, an EPS of $2.52 in the upcoming release would be constructive in reinforcing Apple&#8217;s alignment with the Adhishthana framework.
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="675" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062906/Apple-Fundamentals.png" alt="Apple Fundamentals and YOY comparison" class="wp-image-11457" style="width:684px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062906/Apple-Fundamentals.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062906/Apple-Fundamentals-300x169.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062906/Apple-Fundamentals-1024x576.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/24062906/Apple-Fundamentals-768x432.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Apple Fundamentals </figcaption></figure>
With price behavior hovering near key structural supports and 40 weekly bars remaining to the discovery of the Nirvana level in C6, Apple's next move could help define the shape of its forthcoming market cycle.

Equities

Technicals

Opinion

Trading Ideas

AAPL

Apple: Market Structure And Key Support Levels Ahead Of Q2 Earnings

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $102 price target.

Reiteration

VKTX

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients
Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers
&nbsp;Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, will present&nbsp;new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options.
"Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. "In multiple studies, pelareorep has repeatedly demonstrated its ability to engage the immune system to attack pancreatic cancer tumors, which has the potential to improve outcomes for patients battling this difficult-to-treat cancer."

ONCY

TSX:ONC

Oncolytics Biotech Annunces It Will Present New Data From Cohort 1 Of The Goblet Study At 2025 American Society Of Clinical Oncology Annual Meeting In Chicago May 30-June 3, 2025

Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) lowers FY2025 Adj EPS guidance from $6.91-$7.05 to $6.72-$6.82 vs $6.87 analyst estimate..

Procter & Gamble Lowers FY2025 Adj EPS Guidance from $6.91-$7.05 to $6.72-$6.82 vs $6.87 Est and expects all-in sales for fiscal 2025 to be approximately in-line with the prior year

NDAQ

Nasdaq Q1 Adj. EPS $0.79 Beats $0.77 Estimate, Sales $1.24B Beat $1.23B Estimate

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock, a 13% increase from the previous quarter. The dividend is payable on June 27, 2025 to shareholders of record at the close of business on June 13, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors.

Dividends

Nasdaq Hikes Quarterly Dividend By 13% To $0.27/Shr

KTTA

Pasithea Therapeutics To Present Updated Data From Phase 1 Trial Of PAS-004 At 2025 ASCO Annual Meeting

Ardagh Metal Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>) reported quarterly earnings of $0.02 per share. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $1.27 billion which beat the analyst consensus estimate of $1.17 billion by 8.48 percent. This is a 11.13 percent increase over sales of $1.14 billion the same period last year.

AMBP

Ardagh Metal Packaging Q1 Adj. EPS $0.02 Up From $0.01 YoY, Sales $1.27B Beat $1.17B Estimate

Health Care

NUWE

Nuwellis Received U.S. Patent Covering Fluid Bag Design That Passively Drains Once Full—Reducing The Need For Manual Intervention By Clinical Staff While Preserving The System's Precise Weight-based Measurement

Pool (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) reported quarterly earnings of $1.42 per share which missed the analyst consensus estimate of $1.52 by 6.58 percent. This is a 30.39 percent decrease over earnings of $2.04 per share from the same period last year. The company reported quarterly sales of $1.07 billion which missed the analyst consensus estimate of $1.10 billion by 2.62 percent. This is a 4.55 percent decrease over sales of $1.12 billion the same period last year.

Earnings Misses

Pool Q1 EPS $1.42 Misses $1.52 Estimate, Sales $1.07B Miss $1.10B Estimate

Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) is looking for Q2 GAAP EPS of $0.79-$0.81 vs $0.84 analyst estimate. sees sales of $4.374 billion-$4.417 billion vs $4.47 billion analyst estimate.

TSCO

Tractor Supply Sees Q2 GAAP EPS $0.79-$0.81 vs $0.84 Est; Sees Sales $4.374B-$4.417B vs $4.47B Est

Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) lowers FY2025 GAAP EPS guidance from $6.62-$6.74 to $6.38-$6.50 vs $6.66 analyst estimate..

Procter & Gamble Lowers FY2025 GAAP EPS Guidance from $6.62-$6.74 to $6.38-$6.50 vs $6.66 Est

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates MAG Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#AMEX">MAG</a>) with a Buy and maintains $22 price target.

HC Wainwright & Co. Reiterates Buy on MAG Silver, Maintains $22 Price Target

Rosenblatt analyst Steve Frankel maintains Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) with a Buy and maintains $35 price target.

IMAX

Rosenblatt Maintains Buy on Imax, Maintains $35 Price Target

Extensive pan-cancer validation data from over 3,000 plasma samples to be presented at ASCO
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54243019&amp;newsitemid=20250424920561&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=9c36e2d7b0648c477e4e23a940d6b1d2">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States.
This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In this clinical validation study of more than 3,000 samples from multiple cancer types – including breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma – Signatera Genome was able to detect circulating tumor DNA (ctDNA) significantly ahead of clinical recurrence with excellent performance. In addition, postsurgical Signatera-positive patients had inferior recurrence-free survival compared to Signatera-negative patients, consistently across the different cancers that were evaluated. Additional clinical utility data on the Signatera Genome assay, including predictive data, will be presented at the conference.
Signatera Genome is available in CLIA, IUO and RUO and was designed to improve patient management as an ultra-sensitive assay for the detection of ctDNA. The test's bespoke assay is designed from a whole genome sequence of a patient's tumor and matched normal DNA. It benefits from Natera's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.natera.com%2Fcompany%2Fnews%2Fnatera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd%2F&amp;esheet=54243019&amp;newsitemid=20250424920561&amp;lan=en-US&amp;anchor=patented&amp;index=2&amp;md5=9185737f23159d28b6c15068250d6793">patented</a> multiplex polymerase chain reaction and next generation sequencing technology (mPCR-NGS), using a targeted and deep sequencing approach to detect tiny traces of tumor DNA at frequencies as low as 1 part per million (PPM). An RUO version of the assay is available that detects below 1 PPM.
"We are extremely pleased with the emerging evidence for our Signatera Genome assay, providing an ultrasensitive MRD detection tool for physicians," said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer. "We look forward to sharing the results of this study, which further demonstrates the clinical utility of Signatera across disease indications."

Comments

89bio

空売り

89bio (NASDAQ:ETNB) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル